Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
All articles by Jonathan Goodman, MPhil
Venetoclax With a Hypomethylating Agent Effective in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukemia
Regardless of genotype, venetoclax with a hypomethylating agent yields strong response and survival outcomes among patients with treatment-naive or R/R AML.
Eltrombopag: Noninferior to Intravenous Immunoglobulin in Immune Thrombocytopenia?
Eltrombopag may be an effective alternative to intravenous immunoglobulin for the perioperative treatment of immune thrombocytopenia.
Multiple Myeloma: More Real-World Data Needed To Confirm Effectiveness of New Treatments
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Survival Outcomes and HIV Status Among Patients With Plasmablastic Lymphoma
Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.
Improving Survival in Younger Patients With Waldenström Macroglobulinemia
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
Long-Term Zanubrutinib Treatment Effective for Majority of Patients With Waldenström Macroglobulinemia
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Risk-Stratified Therapy Reduces Late Morbidity, Mortality in Pediatric Acute Lymphoblastic Leukemia
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
Venetoclax With Chemotherapy: Promising for Elderly Patients With AML?
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
Systematic Analysis Reveals Genomic Mutational Frequencies in MCL
The authors noted that these findings should be seen as a reference for the mutational landscape in MCL at baseline and at disease progression after treatment.
-
Loading...
-
Loading...
Next post in Lymphoma
